Alpha-amino Pateamine A Derivatives for CLL Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current α-amino pateamine A derivatives face challenges with therapeutic effectiveness, toxicity, and pharmacokinetic properties, particularly high protein binding in human plasma, which limits their potency and potential as effective therapeutic agents for chronic lymphocytic leukemia (CLL).
Innovation Solution
Development of α-amino pateamine A derivatives with specific structural formulas (I-VIII) and their pharmaceutically acceptable salts, along with antibody drug conjugates for targeted delivery, to inhibit eIF4A-dependent translation initiation and reduce plasma protein binding, enhancing potency and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DMDAPatA is used to inhibit cap-dependent translation initiation, then anti-proliferative activity against cancer cell lines is improved, but plasma protein binding increases leading to reduced in vivo potency
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of DMDAPatA through systematic variation of substituents at positions 2, 4, and 6 of the macrocycle ring. Specific modifications include introducing electron-withdrawing groups (fluoro, chloro, cyano), electron-donating groups (methoxy, hydroxyl), and varying alkyl chain lengths to optimize the balance between anti-proliferative activity and plasma protein binding characteristics.
Solution Approach 2:
The patent applies local quality by making targeted modifications at specific positions of the DMDAPatA molecule rather than global structural changes. The substituents are strategically placed at positions 2, 4, and 6 to locally alter electronic properties and steric characteristics, thereby fine-tuning the molecule's interaction with plasma proteins while preserving the core translation inhibition mechanism.
2Reliability
If PatA derivatives are developed to treat CLL, then therapeutic effectiveness is improved, but toxicity increases
Solution Approach 1:
The patent applies partial action by designing derivatives that selectively target CLL cells through modified structural features while maintaining sufficient potency. The substitutions at positions 2, 4, and 6 provide selective enhancement of anti-CLL activity without proportionally increasing general cytotoxicity, achieving a favorable therapeutic index through partial optimization of the parent compound's properties.
3Ease of manufacture
If DMDAPatA is synthesized as a simplified analog, then ease of synthesis is improved, but plasma protein binding increases reducing bioavailability
Solution Approach 1:
The patent applies composite material principles by creating hybrid structures that combine the simplified DMDAPatA core with various functional substituents. These composite molecules integrate the ease of synthesis advantage of the simplified analog with modified side chains that reduce plasma protein binding, thereby improving overall bioavailability while maintaining synthetic accessibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The α-amino pateamine A derivatives demonstrate potent inhibitory activity against CLL cells with reduced plasma protein binding, making them promising candidates for CLL treatment with improved therapeutic effectiveness and bioavailability.
Implementation Method 1
PatA and DMDAPatA inhibit cap-dependent translation initiation by sequestration of eIF4A that prevents formation of the eIF4F complex
Data Source
AI summary
Pateamine A derivatives and pharmaceutical compositions that include the derivatives. The pateamine A derivatives are α-amino pateamine A derivatives that lack the C5-methyl group of pateamine A.